Journal: Cell reports
Article Title: Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response
doi: 10.1016/j.celrep.2025.115698
Figure Lengend Snippet: (A) Overview of single dose paradigm where tumors are harvested 48 h after a single dose of aPD1 or isotype control in order to capture the initial effects of treatment. (B) UMAP plot depicting an overview of heterogeneity in single-cell transcriptomes derived from responder and non-responder strain tumors and highlighting the T/NK cell cluster. (C) Subclustering of the T/NK cell cluster reveals transcriptionally distinct cell subsets showing enrichment of subclusters 3 and 13 in responding tumors. (D) Fraction of exhausted CTLs (cluster 3) as portion of all cells in responder and non-responder strain groups, Wilcoxon test, *** p < 0.001, * p < 0.05, respectively. (E) Fraction of IFN-γ + CTLs (cluster 13) as portion of all cells in responder and non-responder strain groups, Wilcoxon test, ** p < 0.01; n.s., not significant, respectively. (F) Expression of an 18-gene signature reflecting IFN-γ + stimulation applied to all cells in each cluster (left) or macrophage subcluster (right), with dot size proportional to the relative number of cells of each type, dot color relative to the median IFN-γ + stimulation score, and bars depicting the difference in summed pathway score between responder and non-responder cells within each (sub)cluster. (G) Fraction of IFN-γ-stimulated macrophage clusters (clusters 2, 5, and 26) as a portion of all cells in responder and non-responder strain groups, Wilcoxon test, **** p < 0.0001, * p < 0.05, respectively. (H) Visium spatial transcriptomics images showing expression of CD45 ( Ptprc ) (top row) and Cxcl9 (bottom row) in spatially resolved spots of tumors harvested from responder (CC75F1) and non-responder (CC80F1) mouse tumors. Hematoxylin and eosin stains showed no evidence of necrosis in these tumor sections. (I) Percentage of Ptprc + spatial transcriptomics spots co-expressing either macrophage lineage markers ( Adgre1, Cd68, Itgam , and Cxcl9 ) or dendritic cell markers (Batf3 and/or Zbtb46) along with CTL markers ( Thy1, Cd8a , and Gzmb ) across all tissue regions in responder vs. non-responder strain tumors. **** p < 0.0001, permutation test (see ). See also .
Article Snippet: Anti-Human/Mouse CD11b APC-Cy7 (clone M1/70) , Tonbo Biosciences , CAT#25-0112; RRID:AB_2621625.
Techniques: Control, Derivative Assay, Expressing
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
